" class="no-js "lang="en-US"> AnchorDx - Medtech Alert
Wednesday, September 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
AnchorDx | Pharmtech Focus

AnchorDx

About AnchorDx

AnchorDx

Benchmark Medical

Guangzhou Benchmark Medical Co., Ltd. is committed to building a world-class high-throughput sequencing clinical application and R&D platform, and becoming the world’s leading provider of precision medicine overall solutions. The company’s core team has more than 20 years of senior industry experience and is involved in the fields of cancer genomics, genetics and bioinformatics.
Based on the advantages of core technology and facing precision medicine, the company has established cooperative relationships with upstream, midstream and downstream enterprises and institutions in the industry to form a complete industrial chain from academic research to clinical product transformation. Well-known domestic and foreign hospitals and scientific research institutions have established cooperative relations to develop a series of clinical testing products with independent intellectual property rights and international competitiveness, providing accurate, convenient and comprehensive services for patients, doctors and medical institutions.

Related Story

Appointments

 AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer | Pharmtech Focus

AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer

March 7 2022

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. […]